Follow the Freenome, Inc. share price and the full insider trade history of the company, a listed equity based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Market capitalisation: €1.6bn. The latest transaction was reported on 4 September 2026 (Retenue fiscale). Among the most active insiders: RA CAPITAL MANAGEMENT, L.P.. The full history is free.
15
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Freenome, Inc. Strong Buy (bullish), based on 5 analysts. Average price target: US$18.00.
43Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 20,839 of 27,631 companies
34.4
score / 100
Value
17
Quality
52
FCF yld-7.7%
Earn yld-13%
EV/EBITDA·
ROE-40%
Gross mgn94%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
4,918,411 shares@ US$10.0093.6% of flowCommon StockSEC:0001231919-26-000783:5
15 of 15 declarations
About Freenome, Inc.
Freenome, Inc. is a biotechnology company that uses artificial intelligence to detect cancer at an early stage. It focuses on developing blood-based screening tests to improve patient outcomes.